Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.

Bradley, Todd; Trama, Ashley; Tumba, Nancy; Gray, Elin; Lu, Xiaozhi; Madani, Navid; Jahanbakhsh, Fatemeh; Eaton, Amanda; Xia, Shi-Mao; Parks, Robert; Lloyd, Krissey E; Sutherland, Laura L; Scearce, Richard M; Bowman, Cindy M; Barnett, Susan; Abdool-Karim, Salim S; Boyd, Scott D; Melillo, Bruno; Smith, Amos B; Sodroski, Joseph; Kepler, Thomas B; Alam, S Munir; Gao, Feng; Bonsignori, Mattia; Liao, Hua-Xin; Moody, M Anthony; Montefiori, David; Santra, Sampa; Morris, Lynn; Haynes, Barton F

Bradley, Todd; Trama, Ashley; Tumba, Nancy; Gray, Elin; Lu, Xiaozhi; Madani, Navid; Jahanbakhsh, Fatemeh; Eaton, Amanda; Xia, Shi-Mao; Parks, Robert; Lloyd, Krissey E; Sutherland, Laura L; Scearce, Richard M; Bowman, Cindy M; Barnett, Susan; Abdool-Karim, Salim S; Boyd, Scott D; Melillo, Bruno; Smith, Amos B; Sodroski, Joseph; Kepler, Thomas B; Alam, S Munir; Gao, Feng; Bonsignori, Mattia; Liao, Hua-Xin; Moody, M Anthony; Montefiori, David; Santra, Sampa; Morris, Lynn; Haynes, Barton F.

Afiliação

Bradley T; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: todd.bradley@duke.edu.
Trama A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Tumba N; National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Gray E; National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Lu X; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Madani N; Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Jahanbakhsh F; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Eaton A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Xia SM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Parks R; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Lloyd KE; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Sutherland LL; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Scearce RM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Bowman CM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Barnett S; Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, USA.
Abdool-Karim SS; Center for AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban 4013, South Africa; Columbia University, New York, NY 10032, USA.
Boyd SD; Stanford University, Palo Alto, CA 94305, USA.
Melillo B; University of Pennsylvania, Philadelphia, PA 19104, USA.
Smith AB; University of Pennsylvania, Philadelphia, PA 19104, USA.
Sodroski J; Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Kepler TB; Boston University, Boston, MA 02118, USA.
Alam SM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Gao F; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Bonsignori M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Liao HX; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Moody MA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Montefiori D; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Santra S; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Morris L; National Institute for Communicable Diseases, Johannesburg 2131, South Africa; Center for AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban 4013, South Africa; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2131, South Africa.
Haynes BF; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: barton.haynes@duke.edu.

EBioMedicine ; 12: 196-207, 2016 Oct.

Article em En | MEDLINE | ID: mdl-27612593

Assuntos

Substituição de Aminoácidos; Anticorpos Neutralizantes/imunologia; Anticorpos Anti-HIV/imunologia; Proteína gp41 do Envelope de HIV/genética; Proteína gp41 do Envelope de HIV/imunologia; HIV-1/genética; HIV-1/imunologia; Domínios e Motivos de Interação entre Proteínas/genética; Domínios e Motivos de Interação entre Proteínas/imunologia; Vacinas contra a AIDS/genética; Vacinas contra a AIDS/imunologia; Sequência de Aminoácidos; Animais; Anticorpos Bloqueadores/imunologia; Anticorpos Neutralizantes/genética; Variação Antigênica; Modelos Animais de Doenças; Expressão Gênica; Anticorpos Anti-HIV/genética; Proteína gp120 do Envelope de HIV/genética; Proteína gp120 do Envelope de HIV/imunologia; Proteína gp41 do Envelope de HIV/química; Infecções por HIV/imunologia; Infecções por HIV/prevenção & controle; Infecções por HIV/virologia; Humanos; Imunização; Macaca mulatta; Mutação; Testes de Neutralização

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp41 do Envelope de HIV / HIV-1 / Substituição de Aminoácidos / Domínios e Motivos de Interação entre Proteínas / Anticorpos Neutralizantes Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google